|
1
|
Jemal A, Siegel R, Ward E, Murray T, Xu J,
Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin.
56:106–130. 2006. View Article : Google Scholar
|
|
2
|
Van Cutsem E, Moiseyenko VM, Tjulandin S,
et al: Phase III study of docetaxel and cisplatin plus fluorouracil
compared with cisplatin and fluorouracil as first-line therapy for
advanced gastric cancer: a report of the V325 Study Group. J Clin
Oncol. 24:4991–4997. 2006.
|
|
3
|
Al-Batran SE, Hartmann JT, Hofheinz R, et
al: Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel
(FLOT) for patients with metastatic adenocarcinoma of the stomach
or esophagogastric junction: a phase II trial of the
Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol.
19:1882–1887. 2008. View Article : Google Scholar
|
|
4
|
Cunningham D, Okines AF and Ashley S:
Capecitabine and oxaliplatin for advanced esophagogastric cancer. N
Engl J Med. 362:858–859. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bang YJ, Van Cutsem E, Feyereislova A, et
al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): a phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar
|
|
6
|
Voldborg BR, Damstrup L, Spang-Thomsen M
and Poulsen HS: Epidermal growth factor receptor (EGFR) and EGFR
mutations, function and possible role in clinical trials. Ann
Oncol. 8:1197–1206. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nicholsan RI, Gee JM and Harper ME: EGFR
and cancer prognosis. Eur J Cancer. 37(Suppl 4): S9–S15. 2001.
View Article : Google Scholar
|
|
8
|
Yonemura Y, Sugiyama K, Fujimara T, Kamata
T, Fushida S, Yamaguchi A, et al: Epidermal growth factor receptor
status and S-phase fractions in gastric carcinoma. Oncology.
46:158–161. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jang WI, Yang WI, Lee CI, Kim HS, Song KS,
Cho MY, Park JK and Shim YH: Immunohistochemical detection of p53
protein, c-erbB-2 protein, epidermal growth factor receptor protein
and proliferating cell nuclear antigen in gastric carcinoma. J
Korean Med Sci. 8:293–304. 1993. View Article : Google Scholar
|
|
10
|
García I, Vizoso F, Martín A, Sanz L,
Abdel-Lah O, Raigoso P and García-Muñiz JL: Clinical significance
of the epidermal growth factor receptor and HER2 receptor in
resectable gastric cancer. Ann Surg Oncol. 10:234–241.
2003.PubMed/NCBI
|
|
11
|
Galizia G, Lieto E, Orditura M, Castellano
P, Mura AL, Imperatore V, Pinto M, Zamboli A, De Vita F and
Ferraraccio F: Epidermal growth factor receptor (EGFR) expression
is associated with a worse prognosis in gastric cancer patients
undergoing curative surgery. World J Surg. 31:1458–1468. 2007.
View Article : Google Scholar
|
|
12
|
Gamboa-Dominguez A, Dominguez-Fonseca C,
Quintanilla-Martinez L, Reyes-Gutierrez E, Green D, Angeles-Angeles
A, Busch R, Hermannstädter C, Nährig J, Becker KF, Becker I, Höfler
H, Fend F and Luber B: Epidermal growth factor receptor expression
correlates with poor survival in gastric adenocarcinoma from
Mexican patients: a multivariate analysis using a standardized
immunohistochemical detection system. Mod Pathol. 17:579–587. 2004.
View Article : Google Scholar
|
|
13
|
Lieto E, Ferraraccio F, Orditura M,
Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F and Galizia G:
Expression of vascular endothelial growth factor (VEGF) and
epidermal growth factor receptor (EGFR) is an independent
prognostic indicator of worse outcome in gastric cancer patients.
Ann Surg Oncol. 15:69–79. 2008. View Article : Google Scholar
|
|
14
|
Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK
and Kim WH: EGFR in gastric carcinomas: prognostic significance of
protein overexpression and high gene copy number. Histopathology.
52:738–746. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Matsubara J, Yamada Y, Nakajima TE, Kato
K, Hamaguchi T, Shirao K, Shimada Y and Shimoda T: Clinical
significance of insulin-like growth factor type 1 receptor and
epidermal growth factor receptor in patients with advanced gastric
cancer. Oncology. 74:76–83. 2008. View Article : Google Scholar
|
|
16
|
Terashima M, Kitada K, Ochiai A, Ichikawa
W, Kurahashi I, Sakuramoto S, Sano T, Imamura H and Sasako M;
ACTS-GC Group. Impact of expression of human epidermal growth
factor receptors EGFR and ERBB2 on survival in patients with stage
II/III gastric cancer. Clin Cancer Res. 18:5992–6000. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim JS, Kim MA, Kim TM, Lee SH, Kim DW, Im
SA, Kim TY, Kim WH, Yang HK, Heo DS, Bang YJ, Lee KU, Choe KJ and
Kim NK: Biomarker analysis in stage III-IV (M0) gastric cancer
patients who received curative surgery followed by adjuvant
5-fluorouracil and cisplatin chemotherapy: epidermal growth factor
receptor (EGFR) associated with favourable survival. Br J Cancer.
100:732–738. 2009. View Article : Google Scholar
|
|
18
|
Ye YW, Dong RZ, Zhou Y, Du CY, Wang CM, Fu
H and Shi YQ: Prognostic analysis of familial gastric cancer in
Chinese population. J Surg Oncol. 104:76–82. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Atmaca A, Werner D, Pauligk C, Steinmetz
K, Wirtz R, Altmannsberger HM, Jäger E and Al-Batran SE: The
prognostic impact of epidermal growth factor receptor in patients
with metastatic gastric cancer. BMC Cancer. 12:5242012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Song HS, Do YR, Kim IH, Sohn SS and Kwon
KY: Prognostic significance of immunohistochemical expression of
EGFR and C-erbB-2 oncoprotein in curatively resected gastric
cancer. Cancer Res Treat. 36:240–245. 2004. View Article : Google Scholar : PubMed/NCBI
|
